India-France Join hands to combat Liver, Metabolic diseases

In a significant step forward in the fight against metabolic disorders, India and France have joined hands with the inauguration of the Indo-French Node for Liver & Metabolic Disease Network (InFLiMeN). The initiative was launched by the Institute of Liver and Biliary Sciences (ILBS), India, and the National Institute of Health and Medical Research (INSERM), France, during a ceremony held at ILBS.

Dr. Jitendra Singh, Minister of Science & Technology and Earth Sciences, on the occasion said, “The launch of InFLiMeN marks a significant milestone in India-France collaborative efforts in the field of healthcare. This initiative has the potential to make a real difference in the lives of people suffering from liver and metabolic diseases.

Prof. Shiv K. Sarin, Chancellor, ILBS said, “We are delighted to partner with INSERM on this crucial initiative. InFLiMeN will serve as a vital platform for knowledge sharing and collaborative research, leading to the development of innovative solutions for liver and metabolic diseases.”

InFLiMeN is a collaborative consortium initiated by the Institute of Liver and Biliary Sciences (ILBS), India, and the National Institute of Health and Medical Research (INSERM), France. The node aims to promote joint research activities and develop new technologies for the diagnosis and treatment of liver and metabolic diseases. This first-of-its-kind virtual node will leverage the combined expertise of scientists from both countries to find cost-effective solutions for these critical health issues.

Dr. Didier Samuel, CEO, INSERM (Virtual Address) applauded the initiative and commented, “InFLiMeN is a testament to the strong scientific ties between India and France. This joint effort will undoubtedly accelerate progress in the fight against liver and metabolic diseases. He also shed a light on biomedical reasearch in metabolic and liver diseases, reinforcing international position of INSERM and how alliance of between Indian and French colleagues working in INSERM will strengthen the relations of these two countries for a better patient outcome in liver and metabolic diseases.”